Cart
sales@molnova.com
CSN5i-3 B
CAS No. 2375740-98-8
CSN5i-3 B( —— )
Catalog No. M32870 CAS No. 2375740-98-8
CSN5i-3 is a potent, selective, and orally available inhibitor of the proteolytic subunit of the CSN complex, CSN5.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 575 | Get Quote |
|
| 5MG | 772 | Get Quote |
|
| 10MG | 1169 | Get Quote |
|
| 25MG | 1684 | Get Quote |
|
| 50MG | 2272 | Get Quote |
|
| 100MG | 2997 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCSN5i-3 B
-
NoteResearch use only, not for human use.
-
Brief DescriptionCSN5i-3 is a potent, selective, and orally available inhibitor of the proteolytic subunit of the CSN complex, CSN5.
-
DescriptionCSN5i-3 is a potent, selective and orally available inhibitor of CSN5/Jab1, and inhibits CSN-catalysed Cul1 deneddylation with an IC50 value of 5.8?nM.
-
In VitroCSN5i-3 traps CRLs in the neddylated state, which leads to inactivation of a subset of CRLs by inducing degradation of their substrate recognition module.
-
In VivoCSN5i-3 shows a good pharmacokinetic profile. Treatment with CSN5i-3 triggers the formation of cleaved PARP and cleaved caspase 3 indicative of apoptosis induction.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2375740-98-8
-
Formula Weight505.56
-
Molecular FormulaC28H29F2N5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (197.80 mM)
-
SMILESCC(C)n1nc(cc1C(=O)Nc1ccc([C@H]2[C@@H](O)CCCc3cncn23)c(c1)-c1ccccc1)C(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Schlierf A, et al. Targeted inhibition of the COP9 signalosome for treatment of cancer. Nat Commun. 2016 Oct 24;7:13166.?
molnova catalog
related products
-
TJ191
TJ191 is a selective anti-cancer agent, targeting low TβRIII-expressing malignant T-cell leukemia/lymphoma cells.
-
HNPMI
HNPMI is an EGFR inhibitor that induces G0/G1 phase arrest of CRC cells in colorectal cancer, regulates enzymes associated with apoptosis, and can promote apoptosis, and can be used for the study of colorectal cancer.
-
Declopramide
Declopramide (OXI-104) is a novel chemosensitizer with antitumor activity that induces apoptosis and can be used to study colorectal cancer and inflammatory bowel disease.
